Comparing HIV Vaccine Immunogenicity across Trials with Different Populations and Study Designs
跨人群与研究设计比较 HIV 疫苗免疫原性AI 解读 ↓
← 返回论文列表与筛选
阅读说明
本页整理公开书目信息，不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成，未完成全文核验，可能有误；具体假设、证明与结论请核对原文。摘要保留来源文本，未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要；缺少可靠材料时保留待补状态。
本页为预印本版本；arXiv 收录、作者填写的期刊信息以及作者既有发表经历，都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对，只展示已核实例，档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录，不合计多个记录；关联记录可能包含正式发表版本，不等于此版本单独引用。缺失不视为零，引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配，同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列，再参考通用方法与发表日期。
分类依据与纠错
AI 根据所提供的论文材料归类：摘要明确围绕跨试验标准化比较的因果估计目标、估计量及稳健性质展开。
反馈分类问题
正在核对关联版本…
代码、数据与补充材料
正在核对对应版本的资源…
跨人群与研究设计比较 HIV 疫苗免疫原性
- 研究问题
- 不同 HIV 疫苗试验在人群、规模和研究设计上存在差异，如何定义可比的因果目标并标准化比较疫苗诱导的免疫反应？
- 方法与思路
- 作者提出确定适当因果估计目标与估计量的框架，以模拟评估其表现，再利用三项近期 HIV 疫苗试验的数据进行比较。
- 材料陈述的贡献
- 摘要称框架支持跨试验的标准化免疫原性比较，估计量具有良好表现和稳健性质；具体稳健性形式及比较结果未在摘要展开。
- 阅读关注点
- 应核对标准化的目标人群、跨试验可比性与可迁移条件、嵌套病例对照设计的处理，以及稳健性质所依赖的模型组合。
- 阅读边界
- 这是 arXiv 预印本，同行评审与期刊接收均未核实；摘要未说明识别假设，免疫原性比较也不能直接解释为预防感染效力比较。
原文摘要
Safe and effective preventive vaccines have the potential to help stem the HIV epidemic. The efficacy of such vaccines is typically measured in randomized, double-blind phase IIb/III trials and described as a reduction in newly acquired HIV infections. However, such trials are often expensive, time-consuming, and/or logistically challenging. These challenges lead to a great interest in immune responses induced by vaccination, and in identifying which immune responses predict vaccine efficacy. These responses are termed vaccine correlates of protection. Studies of vaccine-induced immunogenicity vary in size and design, ranging from small, early phase trials, to case-control studies nested in a broader late-phase randomized trial. Moreover, trials can be conducted in geographically diverse study populations across the world. Such diversity presents a challenge for objectively comparing vaccine-induced immunogenicity. To address these practical challenges, we propose a framework that is capable of identifying appropriate causal estimands and estimators, which can be used to provide standardized comparisons of vaccine-induced immunogenicity across trials. We evaluate the performance of the proposed estimands via extensive simulation studies. Our estimators are well-behaved and enjoy robustness properties. The proposed technique is applied to compare vaccine immunogenicity using data from three recent HIV vaccine trials.